BIOX-101 Displays Safety and Efficacy in Spontaneous Intracerebral Hemorrhage

BIOX-101 has demonstrated its safety and efficacy on top of standard-of-care for secondary brain injury in patients with spontaneous intracerebral hemorrhage, according to new data from the BIRCH trial.¹

Presented at the World Stroke Congress (WSC) 2026 in Seoul, Republic of South Korea, by Dimitri Hemelsoet, MD, of the department of neurology at Ghent University Hospital, these data represent a significant step forward for the first-in-class recombinant protein in development at Bioxodes.¹

“Neuroinflammation driven by early neutrophil activation contributes to secondary brain injury after intracerebral hemorrhage (ICH),” Hemelsoet and colleagues wrote. “BIOX-101 is a novel investigational therapy with anti-neutrophil activity and inhibitory effect on coagulation factors XIa/XIIa. We evaluated the safety and efficacy of BIOX-101 added to standard-of-care (SoC) versus SoC alone in first-ever primary ICH.”¹

Structuring the BIRCH Trial

BIRCH was a phase 2a, open-label, randomized proof-of-concept study evaluating the safety, tolerability, and efficacy of BIOX-101 in acute ICH. Patients were eligible for enrollment if they were ≥18 years old and had experienced a first-ever, spontaneous, supratentorial ICH in the cerebral cortex or deep brain structures with a volume ≥5 mL and ≤60 mL, among other criteria. Patients with a history of personal or familial bleeding disorders, as well as a known deficiency in factor XII or hemophilia type A, B, or C, among other criteria, were excluded.^2,3

Patients were randomly assigned in a 3:1 ratio to receive either BIOX-101 on top of SoC or SoC alone. The primary endpoints included the incidence of abnormalities in physical examinations, change in HR and PR interval, and change in blood pressure and heart rate 7 days after randomization. Secondary endpoints included change in perihematomal oedema (PHO) and hemorrhage volumes 10 days after randomization and measurement of the effects of BIOX-101 on the activated Partial Thromboplastin Time (aPTT) and factor XI and XII inhibition.³

A total of 17 patients were assigned to receive BIOX-101, and 6 received only SoC treatment. BIOX-101 was administered as a 48-hour infusion. Hemelsoet and colleagues assessed PK/PD and neutrophil-to-lymphocyte ratio (NLR) ≤168 hours, while safety and functional outcomes, determined by modified Rankin Scale (mRS) scores, were assessed ≤day 360.¹

Outcomes of BIOX-101 Treatment

Hemelsoet and colleagues noted that BIOX-101 achieved active plasma levels within <1 hour, with stable exposure and rapid and reversible pharmacodynamic effects. The aPTT ratio at this timepoint was roughly 2.5. The BIOX-101 cohort also saw greater baseline hematoma and perihematomal edema volumes compared to those receiving only SoC; however, after normalizing to baseline volumes, hematoma expansion and perihematomal edema growth were reduced compared with the SoC arm.¹

By Day 7, DW-MRI showed a low incidence of ischemic lesions or microhemorrhages with BIOX-101, and NLR remained low and stable in the treatment arm while increasing early with only SoC. A favorable shift in mRS was also noted in the BIOX-101 arm.¹

“BIOX-101 is safe, demonstrated rapid target engagement and showed encouraging signals of reduced secondary injury and improved recovery,” Hemelsoet and colleagues wrote. “These findings support advancement to a late-phase trial.”¹

References

1. Hemelsoet D. BIRCH: A Phase IIa Randomized Study of BIOX-101 in Acute Intracerebral Hemorrhage. Presented at the World Stroke Congress (WSC) 2026, Seoul, Republic of South Korea. October 21-23, 2026.

2. Bioxodes S.A. A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Hemorrhage (BIRCH). ClinicalTrials.gov Identifier: NCT05970224. Updated July 23, 2026. Accessed October 21, 2026. https://clinicaltrials.gov/study/NCT05970224?term=NCT05970224&rank=1